

CASE REPORT

Post-COVID-19-associated decline in long-term male fertility and embryo quality during assisted reproductive technology

S. Mannur^{1,*}, T. Jabeen^{2,*}, M.A. Khader ² and L.S.S. Rao²

From the ¹Department of Obstetrics and Gynecology, Angels Fertility Center, Hyderabad 500008, Telangana, India and ²Department of Pharmacology & Pharmacy Practice, Bhaskar Pharmacy College, Jawaharlal Nehru Technical University, Hyderabad 500075, Telangana, India

Address correspondence to Mohd Abdul Khader, Department of Pharmacology & Pharmacy Practice, Bhaskar Pharmacy College, Jawaharlal Nehru Technical University, Hyderabad 500075, Telangana, India. email: khadershoieb46455@gmail.com

*These authors contributed equally to this work.

Learning points for clinicians

- Coronavirus disease 2019 (COVID-19) can impair male fertility with alterations in sperm morphology and DNA integrity could be a major post-COVID-19 complication in men.
- All the clinicians should suggest periodic andrological assessment for COVID-19 'infected' and 'recovered' patients. Further, all the men for ART should be tested for COVID-19 before the procedure.

Case presentation

A South Indian couple with female factor infertility was planned for *in vitro* fertilization at our center. The man was 36 years old and the woman was 32 years old. Ovarian stimulation was achieved through an antagonist protocol. Only one metaphase-2 (M-II) oocyte was collected. The semen analysis of the man on the day of oocyte retrieval revealed 'normozoospermia' (Table 1, Figure 1A). On Day 3, only a single eight-cell embryo with Grade-1 quality (good quality) was formed (Figure 1C). However, in view of the limited number of embryos for transferring and the increasing age of the woman, embryo pooling was planned for the couple. The embryo was frozen at the Day-3 stage.

After 2 days of embryo freezing, unfortunately, the man tested positive for coronavirus disease 2019 (COVID-19). He was experiencing mild symptoms and was prescribed antipyretics, multivitamins and antioxidants. Following continuous treatment, he had tested negative for COVID-19 in 2 weeks. His semen analysis revealed no evidence of virus in the semen. After his recovery, the couple was keen to re-start their *in vitro* fertilization procedure soon, because of their advancing age and diminished ovarian reserve of the woman.

One-month after his recovery from the infection, we started the second stimulation cycle. Three M-II oocytes were collected. To our surprise, the semen analysis of the man taken 43 days after his recovery showed severe 'oligo-astheno-teratozoospermia', with severe sperm DNA damage. There were no acrosomes with dummy and fragmented heads (Table 1, Figure 1B). On Day 3, three embryos of 7–8 cells having Grade-2 quality (poor quality) were formed. The embryos showed severe fragmentation with poor implantation potential (Figure 1D). They were also frozen. We then started antioxidant and multivitamin treatment of coenzyme Q10, lycopene, docosahexaenoic acid, folic acid, selenium and zinc to the man and continued it for 3 months.

Four months post-recovering from COVID-19, the third cycle was planned. Four M-II oocytes were collected. The semen analysis of the man taken 135 days after his recovery showed an improvement in sperm count and motility, but the morphology

Submitted: 3 January 2021; Revised (in revised form): 5 January 2021

© The Author(s) 2021. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.

For permissions, please email: journals.permissions@oup.com

Table 1. Semen analysis findings of man

	First cycle (pre-COVID-19)	Second cycle (1 month post-COVID-19)	Third cycle (4 months post- COVID-19)	Reference range (WHO 2010) ⁶
Microscopic examination				
Sperm concentration (million/ml)	40.4	10	22	≥15
Total sperm count (million/ejaculate)	172	30	67	≥39
Motility				
Progressive motility (%)	51	10	50	≥32
Non-progressive motility (%)	11	50	18	
Non-motile (%)	38	40	32	
Morphology				
Normal forms (%)	12	<1	1	≥4
Abnormal forms (%)	88	>99	99	
Vitality				
Live sperms (%)	76	22	54	≥58
Dead sperms (%)	24	8	46	
Impression	Normozoospermia	Oligo-astheno-teratozoospermia	Teratozoospermia	Normozoospermia
Method	Double density gradient method	Double density gradient method	Double density gradient method	

WHO, World Health Organization.




Figure 1. Sperm and embryo characteristics. (A) Normozoospermia with an excellent sperm count, motility and normal morphology in man before acquiring COVID-19. (B) Oligo-astheno-teratozoospermia with decreased sperm count, motility and normal morphology in man after acquiring COVID-19. (C) Grade-1 quality embryo of couple showing eight cells, with no fragmentation, before the man got infected with COVID-19. (D) Grade-2 quality embryo of couple showing severe fragmentation, after 1 month of man recovery from COVID-19. (E) Grade-2 quality embryo of couple showing severe fragmentation, after 4 months of man recovery from COVID-19.

remains poor with typical characteristics of 'teratozoospermia'. The sperm DNA also remains severely damaged (Table 1). On Day 3, only two embryos were formed with eight cells of Grade-2

quality (poor quality) showing severe fragmentation (Figure 1E). However, due to the severe fragmentation and poor quality, these embryos also cannot be transferred to the woman.

Discussion

To date, there is no convincing proof to validate the long-term impact of COVID-19 infection on important biomarkers of male fertility such as sperm count, motility, morphology and sperm DNA damage among patients recovered from this new infection.¹ In the present case, we report for the first time that COVID-19 can lead to long-term detrimental effects on cardinal male fertility parameters, particularly the sperm DNA and morphology. Owing to the possible repercussions of angiotensin-II upregulation at different stages of spermatozoon's journey consequent to the infection, the intrinsic apoptotic pathway might get stimulated resulting in sperm senescence and cell death. Further, its prolonged exposure may result in premature acrosomal exocytosis and reduction in sperm motility, respectively.^{2,3} Nevertheless, the presence of transmembrane protease, serine 2 (TMPRSS2) in the sperm plasma membrane creates additional evidence of spermatozoa, being a vulnerable target of this infection.⁴ In the present case, we saw even a mild infection can result in long-term alterations in sperm morphology and sperm DNA integrity of men and can take a much longer time (>4 months) than what has been previously thought (70–90 days) for returning to the basal state of sperm parameters⁵ or might ultimately induce male infertility. Additionally, delaying fertility treatments due to COVID-19 may result in failure to conceive as the age of the couple has been established as an important predictor of pregnancy potential in assisted reproductive technology outcomes. Further studies are needed to evaluate the post-COVID-19-associated complications on male fertility and revamp assisted reproductive technology procedures for patients who have recovered from this new infection.

Acknowledgments

We thank the patient for granting permission to publish this information. We also thank Mohammed Ahmedullah

Qureshi, Embryologist, Angels Fertility Center, and Dr A. Srinivasa Rao, Principal, Bhaskar Pharmacy College for their constant support.

Funding

The authors received no specific funding for this work.

Conflict of interest. None declared.

References

1. Seymen CM. The other side of COVID-19 pandemic: Effects on male fertility. *J Med Virol* 2020; **93**:1396–1402.
2. Aitken RJ. COVID-19 and human spermatozoa-potential risks for infertility and sexual transmission? *Andrology* 2020; **9**: 48–52.
3. Olaniyan OT, Dare A, Okotie GE, Adetunji CO, Ibitoye BO, Bamidele OJ, et al. Testis and blood-testis barrier in Covid-19 infestation: role of angiotensin-converting enzyme 2 in male infertility. *J Basic Clin Physiol Pharmacol* 2020; **31**. <https://www.degruyter.com/view/journals/jbcpp/ahead-of-print/article-10.1515-jbcpp-2020-0156/article-10.1515-jbcpp-2020-0156.xml> (31 December 2020, date last accessed).
4. Ji H-L, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. *Physiol Rev* 2020; **100**:1065–75.
5. Sergerie M, Mieusset R, Croute F, Daudin M, Bujan L. High risk of temporary alteration of semen parameters after recent acute febrile illness. *Fertil Steril* 2007; **88**:970.e1–e7.
6. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HG, Behre HM, et al.. World Health Organization reference values for human semen characteristics. *Human Reproduction Update* 2010; **16**:231–45. 10.1093/humupd/dmp048.